Use of the medication Ozempic linked to reduced risk of depression and anxiety
Studies indicate that GLP-1–class medications, such as semaglutide, used to treat diabetes and support weight loss, may offer significant mental health benefits. Researchers from the University of Eastern Finland, the Karolinska Institutet in Sweden, and Griffith University in Australia analyzed data from nearly 100,000 individuals and found an association between the use of these medications and a reduction in psychiatric hospitalizations and medical leave.
Study Highlights Mental Health Benefits of GLP-1 Medications
The research found that the use of GLP-1 medications, such as Ozempic and Wegovy, is linked to a significant decrease in psychiatric hospital visits and in the number of workdays lost due to mental health issues. The study, published in The Lancet Psychiatry, suggests that these medications not only help with weight management but may also have a positive impact on users’ mental health.
Analysis of Data from Nearly 100,000 People
Researchers analyzed data from Sweden’s national health registries, tracking nearly 100,000 individuals between 2009 and 2022. Of these, more than 20,000 had used GLP-1 medications during that period. The analysis allowed comparisons between periods when participants were undergoing treatment and when they were not, revealing a correlation between medication use and improvements in mental health indicators.
Significant Reductions in Hospitalizations and Leave
The results showed that the use of semaglutide was associated with a 42% reduction in psychiatric hospitalizations and a 44% decrease in the risk of depression. In addition, cases of anxiety disorders dropped by 38%. The study also found a 47% reduction in hospitalizations and leave related to substance use during periods when participants were being treated with these medications.
Possible Mechanisms of Action
Although researchers have not been able to determine exactly how GLP-1 medications influence mental health, they suggest that factors such as reduced alcohol consumption and improvements in body image resulting from weight loss may play a role. In addition, changes in how the brain’s reward system functions may be a neurobiological mechanism involved, as noted by research director Markku Lähteenvuo.
These findings reinforce the importance of considering the positive side effects of treatments aimed at physical health, expanding the discussion around the use of GLP-1 medications in clinical practice. The research contributes to a broader understanding of the impacts of these drugs beyond glycemic control and weight loss.
